CD10蛋白在肿瘤中的表达及其临床意义的研究进展

doi:10.3969/j.issn.1004-616x.2017.05.016

摘要/Abstract

摘要： CD10蛋白是一种细胞表面糖蛋白金属结合酶，具有中性肽链内切酶（NEP）的功能，表达于各种组织中且功能不尽相同。目前广泛应用于血液系统肿瘤和部分实体肿瘤的诊断和预后判断，CD10表达往往提示预后不良。本文简要综述CD10蛋白在实体肿瘤中的表达及其在预测肿瘤预后以及生物学行为中的临床意义等相关研究进展。

关键词: 肿瘤, CD10, 中性肽链内切酶, 免疫组织化学

中图分类号:

R730.1

杨修远, 潘月龙. CD10蛋白在肿瘤中的表达及其临床意义的研究进展[J]. 癌变·畸变·突变, 2017, 29(5): 397-401.

[1] MAGUER-SATTA V,BESANÇON R,BACHELARD-CASCALES E. Concise review:neutral endopeptidase (CD10):a multifaceted environment actor in stem cells,physiological mechanisms,and cancer[J]. Stem Cells,2011,29(3):389-396.
[2] IWAYA K,OGAWA H,IZUMI M,et al. Stromal expression of CD10 in invasive breast carcinoma:a new predictor of clinical outcome[J]. Virchows Arch,2002,440(6):589-593.
[3] 刘芸,廖晓龙. CD10分子的研究进展及临床应用[J]. 国际免疫学杂志,2014,37(5):363-366.
[4] KIM J H,HWANG S E,YU H C,et al. Distribution of CD10-positive epithelial and mesenchymal cells in human mid-term fetuses:a comparison with CD34 expression[J]. Anat Cell Biol,2014,47(1):28-39.
[5] KELLER P J,ARENDT L M,SKIBINSKI A,et al. Defining the cellular precursors to human breast cancer[J]. PNAS,2012,109(8):2772-2777.
[6] GREAVES M F,HARIRI G,NEWMAN R A,et al. Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts[J]. Blood,1983,61(4):628-639.
[7] OGAWA H,IWAYA K,IZUMI M,et al. Expression of CD10 by stromal cells during colorectal tumor development[J]. Hum Pathol, 2002,33(8):806-811.
[8] YAO T,TAKATA M,TUSTSUMI S,et al. Phenotypic expression of gastrointestinal differentiation markers in colorectal adenocarcinomas with liver metastasis[J]. Pathology,2002,34(6):556-560.
[9] FUJIMOTO Y,NAKANISHI Y,SEKINE S,et al. CD10 expression in colorectal carcinoma correlates with liver metastasis[J]. Dis Colon Rectum,2005,48(10):1883-1889.
[10] SASAKI T,KUNIYASU H,LUO Y,et al. Serum CD10 is associated with liver metastasis in colorectal cancer[J]. J Surg Res,2014, 192(2):390-394.
[11] FUJITA S,TANIGUCHI H,YAO T,et al. Multi-institutional study of risk factors of liver metastasis from colorectal cancer:correlation with CD10 expression[J]. Int J Colorectal Dis,2010,25(6):681-686.
[12] FUJITA S,YAMAMOTO S,AKASU T,et al. Quantification of CD10 mRNA in colorectal cancer and relationship between mRNA expression and liver metastasis[J]. Anticancer Res,2007,27(5A):3307-3311.
[13] LUO Y,FUJⅡ K,OHMORI H,et al. Antisense phosphorothioate oligodeoxynucleic acid for CD10 suppresses liver metastasis of colorectal cancer[J]. Pathobiology,2009,76(5):267-273.
[14] OHJI Y,YAO T,EGUCHI T,et al. Evaluation of risk of liver metastasis in colorectal adenocarcinoma based on the combination of risk factors including CD10 expression:multivariate analysis of clinicopathological and immunohistochemical factors[J]. Oncol Rep, 2007,17(3):525.
[15] KHANH D T,MEKATA E,MUKAISHO K,et al. Myeloid cells positive for CD10 at invasion front can predict poor outcome in stage Ⅱ colorectal cancer[J]. Int J Clin Oncol,2012,17:240-249.
[16] KHANH D T,MEKATA E,MUKAISHO K,et al. Prognostic role of CD10⁺ myeloid cells in association with tumor budding at the invasion front of colorectal cancer[J]. Cancer Sci,2011,102(9):1724-1733.
[17] JANG T J,PARK J B,LEE J I. The expression of CD10 and CD15 is progressively increased during colorectal cancer development[J]. Korean J Pathol,2013,47(4):340-347.
[18] HIRANO K,NIMURA S,MIZOGUCHI M,et al. Early colorectal carcinomas:CD10 expression,mucin phenotype and submucosal invasion[J]. Pathol Int,2012,62(9):600-611.
[19] DEL RIO P,CRAFA P,PAPADIA C,et al. Is CD10 a reliable marker of invasive colorectal cancer?[J]. Ann Ital Chir,2011,82(4):279-282.
[20] DEL RIO P,CRAFA P,PAPADIA C,et al. Evaluation of CD10 positivity in colorectal polyps in neoplastic transformation[J]. Ann Ital Chir,2010,81(2):121-127.
[21] NISHIDA T,EGASHIRA Y,AKUTAGAWA H,et al. Predictors of lymph node metastasis in T1 colorectal carcinoma:an immunophenotypic analysis of 265 patients[J]. Dis Colon & Rectum,2014,57(8):905-915.
[22] KUNIYASU H,LUO Y,FUJⅡ K,E T al. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoral effect of methionine-enkephalin in the liver[J]. Gut,2010,59(3):348-356.
[23] BERNESCU I,REICHSTEIN A C,LUCHTEFELD M,et al. Does CD10 expression predict lymph node metastasis in colorectal cancer?[J]. Dis Colon Rectum,2016,59(1):22-27.
[24] JANA S H,JHA B M,PATEL C,et al. CD10-a new prognostic stromal marker in breast carcinoma,its utility,limitations and role in breast cancer pathogenesis[J]. Indian J Pathol Microbiol,2014, 57(4):530.
[25] THOMAS S,BABU R J,AGARWAL K,et al. Effect of neoadjuvant chemotherapy on stromal CD10 antigens in breast cancer-A preliminary study[J]. Indian J Cancer,2013,50(1):46.
[26] TAGHIZADEH-KERMANI A,JAFARIAN A H,ASHABYAMIN R,et al. The stromal overexpression of CD10 in invasive breast cancer and its association with clincophathologic factors[J]. Iran J Cancer Prev,2014,7(1):17.
[27] KIM H S,KIM G Y,KIM Y W,et al. Stromal CD10 expression and relationship to the E-cadherin/β-catenin complex in breast carcinoma[J]. Histopathology,2010,56(6):708-719.
[28] WITKIEWICZ A K,FREYDIN B,CHERVONEVA I,et al. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence[J]. Cancer Biol Ther,2010,10(4):391-396.
[29] FLEISCHMANN A,ROCHA C,SAXER-SEKULIC N,et al. High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death[J]. Virchows Arch, 2011,458(6):741-748.
[30] FLEISCHMANN A,SCHLOMM T,HULAND H,et al. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients[J]. Clin Cancer Res,2008,14(23):7838-7842.
[31] HO M E,QUEK S I,TRUE L D,et al. Prostate cancer cell phenotypes based on AGR2 and CD10 expression[J]. Mod Pathol, 2013,26(6):849-859.
[32] OMRAN O M. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma[J]. J Environ Pathol Toxicol Oncol, 2012,31(3).
[33] ABDOU A G. CD10 expression in tumor and stromal cells of bladder carcinoma:an association with bilharziasis[J]. Apmis,2007,115(11):1206-1218.
[34] BAHADIR B,BEHZATOGLU K,BEKTAS S,et al. CD10 expression in urothelial carcinoma of the bladder[J]. Diagn Pathol,2009,4(1):1.
[35] ATIQUE M,ABBASI M S,JAMAL S,et al. CD10 Expression intensity in various grades and stages of urothelial carcinoma of urinary bladder[J]. J Coll Physicians Surg Pak,2014,24(5):351-355.
[36] SEILER R,VON GUNTEN M,THALMANN G N,et al. High CD10 expression predicts favorable outcome in surgically treated lymph node-positive bladder cancer patients[J]. Hum Pathol,2012,43(2):269-275.
[37] BIRCAN S,CANDIR O,KAPUCUOGLU N,et al. CD10 expression in urothelial bladder carcinomas:a pilot study[J]. Urol Int,2006, 77(2):107-113.
[38] 奉松青,郭凯,郑少波,等. 膀胱移行细胞癌CD10的表达及其临床意义[J]. 实用医学杂志,2013,29(7):1117-1119.
[39] HUANG W B,ZHOU X J,CHEN J Y,et al. CD10-positive stromal cells in gastric carcinoma:correlation with invasion and metastasis[J]. Jpn J Clin Oncol,2005,35(5):245-250.
[40] KADOTA K,BUITRAGO D,LEE M C,et al. Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma[J]. Lung Cancer,2015,89(3):329-336.
[41] LEE K W,SUNG C O,KIM J H,et al. CD10 expression is enhanced by twist and associated with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro and in vivo[J]. Int J Cancer,2015,136(2):310-321.
[42] IKENAGA N,OHUCHIDA K,MIZUMOTO K,et al. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer[J]. Gastroenterology,2010,139(3):1041-1051.
[43] 周春辉,黄世章. 胰腺癌细胞中CD10 mRNA的表达与肿瘤恶性程度及转移的关系[J]. 广东医学,2011,32(12):1555-1557.
[44] BRAHAM H,TRIMECHE M,ZIADI S,et al. CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression[J]. Virchows Arch,2006,449(2):220-224.
[45] FUKUSUMI T,ISHⅡ H,KONNO M,et al. CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma[J]. Br J Cancer,2014,111(3):506-514.
[46] KADOTA K,VILLENA-VARGAS J,NITADORI J,et al. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma[J]. Ann Surg Oncol, 2015,22(9):3136-3143.

CD10蛋白在肿瘤中的表达及其临床意义的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	祝欣萍, 贾迪, 林少辉, 刘晨, 李婧铱, 赵炜明. 新型多金属氧酸盐药物{BiW₈O₃₀}对肝癌SK-HEP-1细胞的抑制作用[J]. 癌变·畸变·突变, 2022, 34(1): 47-52,66.
[2]	问天娇, 李思颖, 郑颖, 崔京霞. 脂质体技术在铂类药物抗肿瘤研究中的应用[J]. 癌变·畸变·突变, 2022, 34(1): 72-74.
[3]	刘宁, 梁兰兰, 李淑芳, 沈祥春, 梁冰. 氧化苦参碱对小鼠肉瘤和肝癌的体内外抗肿瘤作用[J]. 癌变·畸变·突变, 2021, 33(6): 426-429,434.
[4]	王蕊, 王珩, 吴娟, 纪晓坤, 郭晓, 马阳, 杜芸. 全自动DNA图像分析系统在胰腺恶性肿瘤诊断中的价值[J]. 癌变·畸变·突变, 2021, 33(6): 451-454.
[5]	张宗敏. 甲状腺微小癌是否需要手术[J]. 癌变·畸变·突变, 2021, 33(5): 325-326.
[6]	孙惠昕, 张茂祥, 王婉莹, 贾海晗, 宋冰冰. 2013—2017年黑龙江省肿瘤登记地区前列腺癌发病死亡情况及趋势分析[J]. 癌变·畸变·突变, 2021, 33(5): 345-348.
[7]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[8]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[9]	王琛瑶, 梁百慧, 吴锦源, 唐梓涵, 许小文, 尹梓健, 丁雅琼, 方雄钊, 李栢芝, 文姝佚, 程转, 詹涵, 张粤烽, 王泫哲, 何仕龙, 张可洵, 刘雅骐, 周飞, 熊兴东, 白春英, 许丽艳, 李恩民. RAC1对恶性肿瘤的调控作用及其分子机制研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 401-404.
[10]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[11]	程书钧. 衰老和恶性肿瘤──防治的思考[J]. 癌变·畸变·突变, 2021, 33(3): 161-162.
[12]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[13]	崔昭阳, 李素娜, 姜旭倩, 王弈丹, 侯丽颖. 芹菜素激活TRAIL死亡受体参与诱导胃癌SGC-7901细胞凋亡的实验研究[J]. 癌变·畸变·突变, 2021, 33(1): 32-36.
[14]	王一帆, 许铭炎, 邓小玲. RNA的N⁶-甲基腺嘌呤甲基化在肿瘤发生中作用的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 77-80.
[15]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.